Can Blinatumomab prevent leukemia from coming back?

Blinatumomab (Blinatumomab) is a novel treatment that has achieved remarkable results in the treatment of acute lymphoblastic leukemia (ALL). While it is effective at controlling leukemia cell growth and achieving remission, whether it can permanently prevent leukemia relapse remains challenging and depends on multiple factors.

The therapeutic effect of belintuzumab first depends on the patient's disease type and severity. For some patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), belintuzumab may result in high response rates or even complete responses, meaning that leukemia cells are effectively controlled during treatment. However, even in complete remission, the risk of relapse remains because some underlying leukemia cells may still be present in the patient's body.

Treatment with belintuzumab is often limited, and after treatment ends, some patients may require maintenance therapy to prolong remission. The risk of relapse may persist during maintenance therapy. In addition, individual differences and the patient's immune system status may also affect whether leukemia will relapse.

The risk of leukemia recurrence still requires close attention during post-treatment monitoring and maintenance periods. Doctors usually perform regular blood tests and other monitoring to detect any possible reappearance of leukemia cells. If there are signs that the leukemia is coming back, doctors may consider adjusting treatment, including continuing belintuzumab or trying other treatments.

In short, belintuzumab can significantly improve the therapeutic effect of B-ALL patients, but it cannot absolutely prevent the recurrence of leukemia. The risk of recurrence remains, so patients require regular monitoring and evaluation by their physician, as well as continued cooperation to take the necessary steps to deal with any possible recurrence. Medical research into the treatment of leukemia is still ongoing, and it is hoped that more effective treatments will emerge in the future.